PEGASUS (NCT03533257) was a Phase 2a, randomized, placebo-controlled trial in 95 participants in the U.S. evaluating safety, tolerability, neurobiological activity, and preliminary clinical efficacy of AMX0035 in a broad range of participants with early dementia or late mild cognitive impairment due to Alzheimer’s disease.
The PEGASUS trial has completed and top line results were presented in November 2021. Read more details in this press release (opens new window).
At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create more moments for the neurodegenerative community.
Our innovative approach to developing transformative therapeutics has far-reaching potential to improve the management of multiple neurodegenerative diseases. Learn more about our clinical trials.
An error has occurred. Please refresh the page and retry.
If you’d like to receive updates about what’s happening at Amylyx, click subscribe.
United States 
Canada
EU
UK